{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T21:58:55Z","timestamp":1794002335617,"version":"4.8.0"},"reference-count":26,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["international-journal-of-gynecological-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Gynecological Cancer"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1136\/ijgc-2023-004842","type":"journal-article","created":{"date-parts":[[2024,1,31]],"date-time":"2024-01-31T12:15:18Z","timestamp":1706703318000},"page":"594-601","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Procedural interventions for oligoprogression during treatment with immune checkpoint blockade in gynecologic malignancies: a case series"],"prefix":"10.1016","volume":"34","author":[{"given":"Tiffany Y","family":"Sia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivian","family":"Wan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Finlan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin C","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexia","family":"Iasonos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Zivanovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukio","family":"Sonoda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3105-8913","authenticated-orcid":false,"given":"Dennis S","family":"Chi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kara","family":"Long Roche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7563-7610","authenticated-orcid":false,"given":"Elizabeth","family":"Jewell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William P","family":"Tew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8217-4554","authenticated-orcid":false,"given":"Roisin E","family":"O'Cearbhaill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seth","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vicky","family":"Makker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying L","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire F","family":"Friedman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chrisann","family":"Kyi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0094-0161","authenticated-orcid":false,"given":"Dmitriy","family":"Zamarin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3955-3238","authenticated-orcid":false,"given":"Ginger","family":"Gardner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1136\/ijgc-2023-004842_bb0010","doi-asserted-by":"crossref","first-page":"4685","DOI":"10.1158\/1078-0432.CCR-21-0327","article-title":"FDA approval summary: pembrolizumab for the treatment of tumor mutational burden-high solid tumors","volume":"27","author":"Marcus","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1136\/ijgc-2023-004842_bb0015","doi-asserted-by":"crossref","first-page":"3753","DOI":"10.1158\/1078-0432.CCR-18-4070","article-title":"FDA approval summary: pembrolizumab for the treatment of microsatellite instability-high solid tumors","volume":"25","author":"Marcus","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1136\/ijgc-2023-004842_bb0020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/JCO.19.02105","article-title":"Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability\/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study","volume":"38","author":"Marabelle","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2023-004842_bb0025","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1056\/NEJMoa2108330","article-title":"Lenvatinib plus pembrolizumab for advanced endometrial cancer","volume":"386","author":"Makker","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1136\/ijgc-2023-004842_bb0030","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1056\/NEJMoa2302312","article-title":"Pembrolizumab plus chemotherapy in advanced endometrial cancer","volume":"388","author":"Eskander","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1136\/ijgc-2023-004842_bb0035","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1056\/NEJMoa2216334","article-title":"Dostarlimab for primary advanced or recurrent endometrial cancer","volume":"388","author":"Mirza","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1136\/ijgc-2023-004842_bb0040","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1056\/NEJMoa2112435","article-title":"Pembrolizumab for persistent, recurrent, or metastatic cervical cancer","volume":"385","author":"Colombo","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1136\/ijgc-2023-004842_bb0045","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.ctrv.2017.07.002","article-title":"Atypical responses in patients with advanced melanoma, lung cancer, renal-cell carcinoma and other solid tumors treated with anti-PD-1 drugs: a systematic review","volume":"59","author":"Queirolo","year":"2017","journal-title":"Cancer Treat Rev"},{"key":"10.1136\/ijgc-2023-004842_bb0050","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/j.clon.2019.05.015","article-title":"The dandelion dilemma revisited for oligoprogression: treat the whole lawn or weed selectively","volume":"31","author":"Patel","year":"2019","journal-title":"Clin Oncol"},{"key":"10.1136\/ijgc-2023-004842_bb0055","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1097\/JTO.0b013e3182745948","article-title":"Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer","volume":"7","author":"Weickhardt","year":"2012","journal-title":"J Thorac Oncol"},{"key":"10.1136\/ijgc-2023-004842_bb0060","doi-asserted-by":"crossref","first-page":"100708","DOI":"10.18632\/oncotarget.20022","article-title":"Outcome of oligoprogressing metastatic renal cell carcinoma patients treated with locoregional therapy: a multicenter retrospective analysis","volume":"8","author":"Santini","year":"2017","journal-title":"Oncotarget"},{"key":"10.1136\/ijgc-2023-004842_bb0065","doi-asserted-by":"crossref","first-page":"642883","DOI":"10.3389\/fonc.2021.642883","article-title":"Progression patterns, treatment, and prognosis beyond resistance of responders to immunotherapy in advanced non-small cell lung cancer","volume":"11","author":"Xu","year":"2021","journal-title":"Front Oncol"},{"key":"10.1136\/ijgc-2023-004842_bb0070","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.lungcan.2021.09.019","article-title":"The role of surgery in the treatment of oligoprogression after systemic treatment for advanced non-small cell lung cancer","volume":"161","author":"Joosten","year":"2021","journal-title":"Lung Cancer"},{"key":"10.1136\/ijgc-2023-004842_bb0075","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1186\/s40425-019-0672-3","article-title":"Patterns of failure after immunotherapy with checkpoint inhibitors predict durable progression-free survival after local therapy for metastatic melanoma","volume":"7","author":"Klemen","year":"2019","journal-title":"J Immunother Cancer"},{"key":"10.1136\/ijgc-2023-004842_bb0080","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.clon.2017.04.035","article-title":"The role of radiotherapy in epidermal growth factor receptor mutation-positive patients with oligoprogression: a matched-cohort analysis","volume":"29","author":"Chan","year":"2017","journal-title":"Clin Oncol"},{"key":"10.1136\/ijgc-2023-004842_bb0085","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.jmoldx.2014.12.006","article-title":"Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): a hybridization capture-based next-generation sequencing clinical assay for solid tumor molecular oncology","volume":"17","author":"Cheng","year":"2015","journal-title":"J Mol Diagn"},{"key":"10.1136\/ijgc-2023-004842_bb0090","article-title":"Reliable pan-cancer microsatellite instability assessment by using targeted next-generation sequencing data","volume":"2017","author":"Middha","year":"2017","journal-title":"JCO Precis Oncol"},{"key":"10.1136\/ijgc-2023-004842_bb0095","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1093\/bioinformatics\/btt755","article-title":"MSIsensor: microsatellite instability detection using paired tumor-normal sequence data","volume":"30","author":"Niu","year":"2014","journal-title":"Bioinformatics"},{"key":"10.1136\/ijgc-2023-004842_bb0100","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1097\/01.pas.0000213428.61374.06","article-title":"Utility of immunohistochemistry in predicting microsatellite instability in endometrial carcinoma","volume":"31","author":"Modica","year":"2007","journal-title":"Am J Surg Pathol"},{"key":"10.1136\/ijgc-2023-004842_bb0105","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.2307\/2532836","article-title":"Resampling procedures to compare two survival distributions in the presence of right-censored data","volume":"52","author":"Heller","year":"1996","journal-title":"Biometrics"},{"key":"10.1136\/ijgc-2023-004842_bb0110","year":"2022"},{"key":"10.1136\/ijgc-2023-004842_bb0115","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12041046","article-title":"Oligoprogressive non-small-cell lung cancer under treatment with PD-(L)1 inhibitors","volume":"12","author":"Rheinheimer","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1136\/ijgc-2023-004842_bb0120","doi-asserted-by":"crossref","first-page":"35","DOI":"10.2147\/JHC.S290197","article-title":"Efficacy of local therapy for oligometastatic hepatocellular carcinoma: a propensity score matched analysis","volume":"8","author":"Kim","year":"2021","journal-title":"J Hepatocell Carcinoma"},{"key":"10.1136\/ijgc-2023-004842_bb0125","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1245\/s10434-019-08099-9","article-title":"Survival outcomes after metastasectomy in melanoma patients categorized by response to checkpoint blockade","volume":"27","author":"Bello","year":"2020","journal-title":"Ann Surg Oncol"},{"key":"10.1136\/ijgc-2023-004842_bb0130","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines10102481","article-title":"Oligoprogression of solid tumors on immune checkpoint inhibitors: the impact of local ablative radiation therapy","volume":"10","author":"Sindhu","year":"2022","journal-title":"Biomedicines"},{"key":"10.1136\/ijgc-2023-004842_bb0135","first-page":"100216","article-title":"Durable disease control with local treatment for oligoprogression of metastatic solid tumors treated with immune checkpoint blockade","volume":"25","author":"Sindhu","year":"2020","journal-title":"Cancer Treat Res Commun"}],"container-title":["International Journal of Gynecological Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X24013458?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X24013458?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ijgc-2023-004842","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T01:29:49Z","timestamp":1753234189000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1048891X24013458"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":26,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["S1048891X24013458"],"URL":"https:\/\/doi.org\/10.1136\/ijgc-2023-004842","relation":{},"ISSN":["1048-891X"],"issn-type":[{"value":"1048-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Procedural interventions for oligoprogression during treatment with immune checkpoint blockade in gynecologic malignancies: a case series","name":"articletitle","label":"Article Title"},{"value":"International Journal of Gynecological Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ijgc-2023-004842","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 IGCS and ESGO 2024. No commercial re-use. See rights and permissions. Published by BMJ.","name":"copyright","label":"Copyright"}]}}